Lynn Kirkpatrick - 25 May 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Role: Chief Executive Officer, Director
Signature: /s/ Lynn Kirkpatrick
Issuer symbol: ENSC
Transactions as of: 25 May 2022
Net transactions value: +$48,298
Form type: 4
Filing time: 27 May 2022, 14:05:01 UTC
Previous filing: 24 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENSC	Common Stock	Purchase	$34,083	+70,000	+25%	$0.4869	354,851	25 May 2022	Direct
transaction	ENSC	Common Stock	Purchase	$14,216	+27,000	+7.6%	$0.5265	381,851	26 May 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENSC	Stock Option	Award		+200,000	+8.6%		2,516,939	17 Feb 2022	Common Stock	200,000	$1.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.

Content

On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.